Immunohistochemical expression of MMP-14 and MMP-2, and MMP-2 activity during human ovarian follicular development

Reproductive Biology and Endocrinology

Leon FAG Massuger³  Toin H van Kuppevelt¹  Jesper MJ Smeenk⁴  Ella AM de Boed²  Jessie TJ Last²  Anneke AM van der Wurff²  Maria Caroline Vos³ 

[1]Department of Biochemistry, Nijmegen Centre for Molecular Life Sciences, Radboud university medical center, PO Box 9101, 6500 HB Nijmegen, the Netherlands

[2]Department of Pathology, St. Elisabeth Hospital, PO Box 90151, 5000 LC Tilburg, the Netherlands

[3]Department of Obstetrics and Gynaecology, Radboud university medical center, PO Box 9101, 6500 HB Nijmegen, the Netherlands

[4]Department of Obstetrics and Gynaecology, St. Elisabeth Hospital, PO Box 90151, 5000 LC Tilburg, the Netherlands

关键词: Matrix metalloproteinases;    Menstrual cycle;    Ovary;    Female reproductive tract;   

Others  :  804764
DOI  :  10.1186/1477-7827-12-12

 received in 2013-10-18, accepted in 2014-01-27,  发布年份 2014

【 摘 要 】

Background

The aim of this study was to investigate the presence of MMP-14 and MMP-2 during human ovarian follicular development using immunohistochemistry, and the activity of MMP-2 in follicular fluid using zymography.

Methods

Ovarian tissue collected from the archives of the Department of Pathology was examined and medical records and histopathology were reviewed. Follicular fluids were collected at the IVF-department and analyzed using zymography.

Results

MMP-14 and MMP-2 were increasingly found in the growing follicles and MMP-2 was highly expressed in the corpus luteum. Pro-MMP-2 was present in follicular fluid of IVF-patients.

Conclusions

The presence of MMP-14 and MMP-2 during human ovarian follicular development from the primordial follicle to the tertiary follicle and corpus luteum is confirmed, as was indicated by earlier animal studies following stimulation with gonadotrophins.

【 授权许可】

   
2014 Vos et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

Figure 10.

Figure 11.

Figure 12.

Figure 13.

【 参考文献 】

• [1]Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole AR, Pidoux I, et al.: MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999, 99(1):81-92.
• [2]Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994, 370(6484):61-65.
• [3]Yoshizaki T, Sato H, Furukawa M: Recent advances in the regulation of matrix metalloproteinase 2 activation: from basic research to clinical implication (Review). Oncol Rep 2002, 9(3):607-611.
• [4]Holmbeck K, Bianco P, Yamada S, Birkedal-Hansen H: MT1-MMP: a tethered collagenase. J Cell Physiol 2004, 200(1):11-19.
• [5]Wahlberg P, Boden I, Paulsson J, Lund LR, Liu K, Ny T: Functional corpora lutea are formed in matrix metalloproteinase inhibitor-treated plasminogen-deficient mice. Endocrinology 2007, 148(3):1226-1234.
• [6]Curry TE Jr, Osteen KG: The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocr Rev 2003, 24(4):428-465.
• [7]Jo M, Thomas LE, Wheeler SE, Curry TE Jr: Membrane type 1-matrix metalloproteinase (MMP)-associated MMP-2 activation increases in the rat ovary in response to an ovulatory dose of human chorionic gonadotropin. Biol Reprod 2004, 70(4):1024-1032.
• [8]Baka S, Zourla K, Kouskouni E, Makrakis E, Demeridou S, Tzanakaki D, Hassiakos D, Creatsas G: Matrix metalloproteinases 2 and 9 and their tissue inhibitors in the follicular fluid of patients with polycystic ovaries undergoing in vitro fertilisation. In Vivo 2010, 24(3):293-296.
• [9]Riley SC, Thomassen R, Bae SE, Leask R, Pedersen HG, Watson ED: Matrix metalloproteinase-2 and -9 secretion by the equine ovary during follicular growth and prior to ovulation. Anim Reprod Sci 2004, 81(3–4):329-339.
• [10]Bakke LJ, Dow MP, Cassar CA, Peters MW, Pursley JR, Smith GW: Effect of the preovulatory gonadotropin surge on matrix metalloproteinase (MMP)-14, MMP-2, and tissue inhibitor of metalloproteinases-2 expression within bovine periovulatory follicular and luteal tissue. Biol Reprod 2002, 66(6):1627-1634.
• [11]Lind AK, hm-Kahler P, Weijdegard B, Sundfeldt AK, Brannstrom M: Gelatinases and their tissue inhibitors during human ovulation: increased expression of tissue inhibitor of matrix metalloproteinase-1. Mol Hum Reprod 2006, 12(12):725-736.
• [12]Manase K, Endo T, Henmi H, Kitajima Y, Yamazaki K, Nishikawa A, Mitaka T, Sato H, Kudo R: The significance of membrane type 1 metalloproteinase in structural involution of human corpora lutea. Mol Hum Reprod 2002, 8(8):742-749.
• [13]Margulies IM, Hoyhtya M, Evans C, Stracke ML, Liotta LA, Stetler-Stevenson WG: Urinary type IV collagenase: elevated levels are associated with bladder transitional cell carcinoma. Cancer Epidemiol Biomarkers Prev 1992, 1(6):467-474.
• [14]Kamat AA, Fletcher M, Gruman LM, Mueller P, Lopez A, Landen CN Jr, Han L, Gershenson DM, Sood AK: The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res 2006, 12(6):1707-1714.
• [15]Waas ET, Wobbes T, Ruers T, Lomme RM, Hendriks T: Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease. Eur J Surg Oncol 2006, 32(7):756-763.
• [16]Jo M, Thomas LE, Wheeler SE, Curry TE Jr: Membrane type 1-matrix metalloproteinase (MMP)-associated MMP-2 activation increases in the rat ovary in response to an ovulatory dose of human chorionic gonadotropin. Biol Reprod 2004, 70(4):1024-1032.
• [17]Kelty BP, Curry TE Jr: Ovarian furin (proprotein convertase subtilisin/kexin type3): expression, localization, and potential role in ovulation in the rat. Biol Reprod 2010, 83(1):147-154.
• [18]Goldman S, Shalev E: MMPS and TIMPS in ovarian physiology and pathophysiology. Front Biosci 2004, 9:2474-2483.
• [19]Kirmse R, Otto H, Ludwig T: The extracellular matrix remodeled: interdependency of matrix proteolysis, cell adhesion, and force sensing. Communicative & Integrative Biology 2012, 5(1):71-73.
• [20]Wolf K, Te Lindert M, Krause M, Alexander S, Te Riet J, Willis AL, Hoffman RM, Figdor CG, Weiss SJ, Friedl P: Physical limits of cell migration: Control by ECM space and nuclear deformation and tuning by proteolysis and traction force. J Cell Biol 2013, 201(7):1069-1084.
• [21]Snoek-van Beurden PA, Von den Hoff JW: Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques 2005, 38(1):73-83.